Biomolecular movies: ChromoTek introduces Chromobody® plasmids

Posted by Katrin Schmidthals on Mar 11, 2013 10:09:00 AM

ChromoTek GmbH (Munich, Germany) offers nanobody based real time assays to visualize and measure the action of candidate drugs or other substances of interest on important regulatory processes in living cells. Presently, four Chromobody® plasmids are available for analyzing the cell cycle, apoptosis, DNA methylation and cytoskeleton dynamics.


Chromobody plasmidA major advantage of the new Chromobody® plasmids compared to Chromobody® cell lines already on the market is that researchers can now monitor cellular pathways in their own cells or cell lines simply by carrying out a transfection. Unlike conventional end point assays, the Chromobody® plasmids allow to follow the fate of endogeneous target proteins over time like in a movie. As the fluorescently labeled intracellular antibodies expressed from these plasmids do not interfere with the activity of their targets, they are extremely useful for high content screening.

The new product format is equally suitable for academic researchers who want to decipher cellular pathways and to biotech/pharma researchers who seek to enhance their drug discovery and high throughput screening capabilities. “We are glad to be able to offer our customers a new product format that gives them greater flexibility both in basic cell biology research and in drug discovery and validation processes” states Marion Jung, Managing Director of ChromoTek.

Customers who would like to try the Chromobody® technology for their own applications can now choose between three options: they can license a cell line, order assay-ready frozen instant cells via ChromoTek or via CCS (Cell Culture Service, now part of Evotec AG) or purchase a Chromobody® plasmid.

These products have recently been featured at the Forum 2013 (European Lab Robotics Interest Group) in Darmstadt.

About ChromoTek

ChromoTek products set new benchmarks for cellular research. The company was established in 2008 as a spin-off from Munich’s Ludwig Maximilian University and is located in Martinsried, Germany’s leading biotech cluster. ChromoTek develops and markets immunological and bioimaging reagents and cellular assays for biomedical research and drug discovery. These include the GFP-Trap® for the rapid pull-down of GFP fusion proteins, GFP- and RFP-Booster for intensifying the fluorescence signal of GFP or RFP fusion proteins, Chromobody® based live cell assays for screening and validation and a fluorescence based protein-protein interaction assay called Fluorescent-2-Hybrid (F2H® Assay). Around 3,000 customers from all over the world trust in ChromoTek products. 

Download Press release

Posted by Katrin on Mar 11, 2013 

Topics: Chromobodies, Nano-Traps, Nano-Booster, F2H assay, GFP-Trap, Nano-Trap, high content analysis, HCA, Chromobody, Chromobody plasmid

News about Nanobodies

For researchers interested in

  • New Nanobody based tools
  • Tips and tricks
  • Featured publications

Recent Posts

Posts by Tag

See all